E5564

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sepsis

Conditions

Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection

Trial Timeline

Oct 1, 2001 → Apr 1, 2005

NCT ID

NCT00046072

About E5564

E5564 is a phase 2 stage product being developed by Eisai for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00046072. Target conditions include Sepsis, Shock, Septic, Sepsis Syndrome.

What happened to similar drugs?

9 of 19 similar drugs in Sepsis were approved

Approved (9) Terminated (1) Active (9)

✅MeropenemPfizerApproved

✅ImipenemMerckApproved

✅Drotrecogin Alfa (activated)Eli LillyApproved

✅Drotrecogin alfa (activated)Eli LillyApproved

✅Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved

✅drotrecogin alfa (activated)Eli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00756912	Phase 1	Terminated	Sep 1, 2008	—	Leukemia
NCT00046072	Phase 2	Completed	Oct 1, 2001	Apr 1, 2005	Sepsis

Competing Products

20 competing products in Sepsis

See all competitors

Product	Company	Stage	Hype Score
Alkaline Phosphatase + Placebo	AM-Pharma	Phase 2	25
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
Meropenem	Pfizer	Approved	43
Imipenem	Merck	Approved	39
Cefiderocol	Shionogi	Phase 1	29
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
Drotrecogin Alfa (Activated) + placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin Alfa (activated)	Eli Lilly	Approved	43
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
sPLA2 Inhibitor	Eli Lilly	Phase 1/2	32
Drotrecogin alfa (activated)	Eli Lilly	Approved	43
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
AZD9773 (CytoFab)	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD4144 + Placebo	AstraZeneca	Phase 2	42